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The dopamine hypothesis of schizophrenia is based
on evidence that the major antipsychotic drugs act
by blocking dopamine D2 receptors and that dopa-
mine-releasing drugs worsen symptoms. In this issue
of Neuron, Kellendonk et al. report an elegant condi-
tional transgenic mouse overexpressing dopamine
D2 receptors selectively in the striatum. Strikingly,
these animals display selective cognitive impairment
typically associated with frontal cortical defects and
abnormal dopamine markers in the prefrontal cortex,
suggesting that striatal dopamine receptors can influ-
ence cortical dopamine function.
The dopamine hypothesis of schizophrenia derives from
a concatenation of diverse evidence (Snyder, 1976). The
initial, most compelling findings were pharmacologic. In
1963, Arvid Carlsson observed changes in levels of do-
pamine metabolites in rats treated with antipsychotic
neuroleptic drugs and speculated that these may reflect
augmented firing of dopamine neurons secondary to
blockade of receptors. The ability to monitor dopamine
receptors by ligand binding permitted the discovery of
very potent and selective blockade of dopamine D2 re-
ceptors by neuroleptic drugs with molecular potencies
paralleling therapeutic potencies. Amphetamine, which
releases dopamine, selectively exacerbates schizo-
phrenic symptoms.
Patricia Goldman-Rakic (Goldman-Rakic, 1999) es-
tablished a role for the dopamine neurons that project
to the prefrontal cerebral cortex in regulating cognitive
functions that are selectively impaired in schizo-
phrenics. Dopamine projections to the prefrontal cortex
arise from the ventral tegmental area of the midbrain.
The most prominent dopamine pathway has cell bodies
in the substantia nigra with axons projecting to the cau-
date and putamen collectively called the striatum. De-
generation of this pathway gives rise to the symptoms
of Parkinson’s disease so that the striatum has generallybeen assigned a primary role in regulating motor behav-
ior. However, the striatum can influence the cerebral
cortex via projections to the pallidum, thence to the thal-
amus, and onward to the cortex.
Dopamine might modulate schizophrenic behavior
without being fundamental to the disease’s pathophys-
iology. A direct link comes from studies reporting in-
creased numbers of dopamine D2 receptors in the stria-
tum of schizophrenic brain (Seeman and Kapur, 2000).
However, prolonged treatment with neuroleptics leads
to augmented numbers of D2 receptors, and there are
few drug-naive schizophrenics.
If hyperactivity of dopamine systems mediated by
augmented numbers of D2 receptors underlies schizo-
phrenic dysfunction, then a transgenic mouse overex-
pressing D2 receptors might provide an animal model
of schizophrenia. In this issue of Neuron, Kellendonk
et al. (2006) have aimed to create such a model by creat-
ing D2 receptor transgenic mice. Most elegant about
this system is that the transgene is conditional, being
under the control of a tetracycline response element
that can be turned off by oral administration of the anti-
biotic doxycycline. Additionally, the transgene is selec-
tively expressed in the striatum and not in other areas
of the brain that possess D2 receptors. The striatum of
the transgenic mice displays increased numbers of D2
receptor binding sites and increased effects on adenylyl
cyclase indicating that the transgenic receptors are
functional. Overall behavior of the mutant mice is normal
with unaltered locomotor activity, sensorimotor gating,
and generalized anxiety. However, the mice display sub-
stantial defects in working memory tasks and behavioral
flexibility typically associated with prefrontal cortical
function. The authors provide direct evidence that the
striatal D2 receptors somehow influence the cortex
because the mutant mice display altered glucose me-
tabolism, dopamine levels, and dopamine D1 receptor
activation in the prefrontal cortex. Reversal of the trans-
gene with doxycycline treatment does not reverse the
cognitive defects, indicating that the behavioral deficit
presumably reflects D2 receptor overexpression during
fetal life.
The Kellendonk study clearly establishes an influence
of striatal D2 receptors upon biochemical markers and
cognitive behaviors associated with the prefrontal cor-
tex. Do these findings teach us about the pathophysiol-
ogy of schizophrenia? Do these mice provide an animal
model of schizophrenia? Recent genetic studies afford
a basis for optimism. Numerous workers have had some
success in identifying specific genes linked to schizo-
phrenia. Best characterized is DISC1, a cytoskeletal pro-
tein that binds to a subtype of phosphodiesterase and
inhibits its catalytic activity (Millar et al., 2005). Because
this phosphodiesterase metabolizes cyclic AMP, which
is a second messenger for dopamine, one might specu-
late about some relationship. Weinberger and col-
leagues (Winterer and Weinberger, 2004) provided
evidence that polymorphisms in catechol-O-methyl-
transferase (COMT) impact dopamine transmission in
prefrontal cortex, prefrontal-linked cognitive behavior,
and schizophrenic behavior. Thus, it is not at all far-
fetched to envisage dopamine disturbances eliciting
schizophrenic mental aberrations. In this case, the trans-
genic mice developed by Kellendonk and colleagues
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485may provide a valuable tool for understanding this most
malignant of mental disorders.
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